| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/15/2004 | WO2004004703A1 m-PHENYLENEDIAMINE DERIVATIVE |
| 01/15/2004 | WO2004004698A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | WO2004004665A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 01/15/2004 | WO2004004656A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003084936A8 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003053401A3 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 01/15/2004 | WO2003047520A3 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010124 CD16A binding proteins and use for the treatment of immune disorders |
| 01/15/2004 | US20040010023 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010017 Antithrombotic agents |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040010009 Excellent inhibitory activity against factor Xa |
| 01/15/2004 | US20040010007 Also thio, sulfoxy and sulfonyl derivatives; imidazotetrazolopyrimidines and intermediates |
| 01/15/2004 | US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009981 Oxazole, thiazole, 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives of pyrimidines, 1,2,4- and 1,3,5-triazines |
| 01/15/2004 | US20040009974 Pyrimidylamino- or triazinylamino- substituted pyrazoles or 1,2,3-triazoles |
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009905 Templates consist of cyclized peptides containing at least two residues in said cyclized peptide are joined by a naphthyl ring; and having bonded to it a linear peptide |
| 01/15/2004 | US20040009248 Method for improving the cell protection |
| 01/15/2004 | US20040009233 Shark meat extract |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040007540 Selective deleukocytation unit for a platelet product |
| 01/15/2004 | DE10229070A1 Phenylderivate 5 Phenyl derivatives 5 |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491994A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491479A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380579A1 Novel physiologically active substances |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1379994A2 Extracorporeal blood processing information management system |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379533A2 Novel cyclo azaphospha hydrocarbons |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379508A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379506A2 Substituted carboxamides |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379271A1 Method for treating von willebrand's disease |
| 01/14/2004 | EP1379266A2 Modified annexin proteins and methods for preventing thrombosis |
| 01/14/2004 | EP1379262A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 01/14/2004 | EP1379254A1 Use of bile acid or bile salt fatty acid conjugates |
| 01/14/2004 | EP1379253A1 Methods of making and pharmaceutical formulations comprising 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 01/14/2004 | EP1379246A1 Nociceptin analogs |
| 01/14/2004 | EP1379245A1 1, 4, 5, 6-tetrahydropyrazolo- 3, 4-c]-pyrid in-7-ones as factor xa inhibitors |
| 01/14/2004 | EP1379244A1 1,4,5,6-tetrahydropyrazolo- 3,4-c]-pyridin-7-ones as factor xa inhibitors |
| 01/14/2004 | EP1379243A1 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 01/14/2004 | EP1379230A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 01/14/2004 | EP1379221A2 Pharmaceutical product with reticulated crystalline microstructure |
| 01/14/2004 | EP1379134A1 Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions |
| 01/14/2004 | EP1379125A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 01/14/2004 | EP0939644B1 Enhanced stimulation of erythropoiesis |
| 01/14/2004 | EP0690991B2 Novel anticoagulant cofactor activity |
| 01/14/2004 | CN1468310A Method for constructing cell strain of expression mutation type human tissue plasmin activator and preparation method of expressing protein |
| 01/14/2004 | CN1468232A Heterocyclic sodium/proton exchange inhibitors and method |
| 01/14/2004 | CN1468226A Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 01/14/2004 | CN1468215A 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 01/14/2004 | CN1468104A Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 01/14/2004 | CN1467224A Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
| 01/14/2004 | CN1467217A Structure and uses of autisense oligodeoxynucleotide for treating thrombus disease |
| 01/14/2004 | CN1466969A Chinese traditional medicine for treating purpuric disease and method for making the same |
| 01/14/2004 | CN1466945A Slow releasing micropill containing active component of indapamide and method for preparing the same |
| 01/14/2004 | CN1134539C Thrombopoietin |
| 01/14/2004 | CN1134451C Inhibitor of collagen-stimulated platelet aggregation |
| 01/14/2004 | CN1134430C Crystal modification of N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 01/14/2004 | CN1134423C Adhesion receptor antagonists |
| 01/14/2004 | CN1134420C Novel substituted imidazole compounds |
| 01/14/2004 | CN1134264C Antithrombotic agents |
| 01/13/2004 | US6677440 Isolating by anion- and/or cation-exchange chromatography at ph value below isoelectric point of protein to be isolated or combination of ion exchange chromatography with affinity chromatography and/or fractional precipitation at specified ph |
| 01/13/2004 | US6677369 Antithrombotic agents |
| 01/13/2004 | US6677356 Concurrently administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with angiotensin converting enzyme inhibitor,calcium channel blocker, adrenergic blocking agent, vasodilator or diuretic |
| 01/13/2004 | US6677354 Treating sleep, brain, sexual, cardiovascular, nervous system, psychological, glandular, and gastrointestinal disorders |
| 01/13/2004 | US6676971 Crosslinked macromolecules |
| 01/13/2004 | US6676947 Use of erythropoietin for the treatment of haemochromatoses |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/10/2004 | CA2434951A1 A selective deleukocytation unit for a platelet product |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004003016A2 Marked peptides having affinity for a phospholipid and uses |
| 01/08/2004 | WO2004003015A2 Peptides having affinity for a phospholipid and uses |
| 01/08/2004 | WO2004002961A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | WO2004002549A1 Use of organic compounds |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |